A putative therapeutic target in Gaucher disease: P04062

Ablatotech Signals reports today on a putative therapeutic target — P04062 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in Gaucher disease.

Background

The protein associated with UniProt accession P04062 is a putative target that warrants experimental validation for its potential role in Gaucher disease. Gaucher disease is a rare genetic disorder caused by mutations in the GBA gene, leading to a deficiency in the enzyme glucocerebrosidase. This deficiency results in the accumulation of glucocerebroside in various tissues, causing a range of symptoms including organ enlargement, bone pain, and neurological complications. Targeting P04062 may offer new therapeutic avenues for managing this condition.

Data-mining rationale

The identification of P04062 as a candidate for Gaucher disease therapy arises from a systematic cross-referencing of UniProt's reviewed human entries related to Gaucher disease against 18 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, P04062 has been observed in expression-profiling studies; however, there are currently no registered Phase 1 or higher clinical programs associated with this target, highlighting a potential area for further exploration.

Why prior analyses may have missed this

Many of the GEO datasets that include expression data relevant to P04062 were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma. As a result, these earlier analyses may not have adequately addressed multiple-testing corrections, which could lead to missed or inaccurately interpreted expression signals. A re-analysis of these datasets using contemporary statistical techniques could provide new insights into the expression dynamics of P04062 in the context of Gaucher disease.

Reasoning for further validation

To further investigate the potential of P04062 as a therapeutic target for Gaucher disease, several experimental approaches are recommended: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes through quantitative PCR (qPCR) in an independent cohort to confirm expression changes. 3. Assess the tissue specificity of P04062 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in Gaucher disease-affected tissues. 4. Employ pathway analysis tools like STRING and OmniPath to explore the biological context and interactions of P04062 within relevant cellular pathways. 5. If validation is achieved, evaluate the druggability of P04062 through databases such as DGIdb and ChEMBL to assess its potential as a therapeutic target.

References